NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-013-2018-0-JP-08 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development JP National Stage 2020-515262 Pending
NCI E-013-2018-0-JP-09 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development JP National Stage 2022-031887 Pending
NCI E-205-2016-0-US-05 NANOPARTICLE TO TARGET CANCER US National Stage 16/084,942 11246881 Issued PDF
NIAID E-118-2016-0-NZ-13 Live Attenuated Zika Virus Vaccine NZ National Stage 746349 Abandoned
NIAID E-118-2016-0-AU-03 Live Attenuated Zika Virus Vaccine AU National Stage 2017230112 Abandoned
NIA E-013-2010-0-US-15 THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS US CON 16/129,470 10617654 Issued PDF
NIA E-139-2012-2-US-13 (R,R')-4'-methoxy-1-naphthylfenoterol (MNF) For The Treatment Of Glioblastomas And Hepatocellular Carcinomas US CON 16/129,569 10485771 Issued PDF
NCI E-078-2016-0-EP-04 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF EP National Stage 17706653.7 Abandoned
NIDA E-053-2016-1-US-04 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders US National Stage 16/084,093 11299476 Issued PDF
NIDA E-053-2016-1-AT-07 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders AT EP 17711971.6 Issued
NIDA E-053-2016-1-BE-08 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders BE EP 17711971.6 Issued
NIDA E-053-2016-1-FR-15 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders FR EP 17711971.6 Issued
NIDA E-053-2016-1-DE-11 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders DE EP 17711971.6 Issued
NIDA E-053-2016-1-FI-14 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders FI EP 17711971.6 Issued
NIDA E-053-2016-1-TR-31 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders TR EP 17711971.6 Issued
NIDA E-053-2016-1-CH-09 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders CH EP 17711971.6 Issued
NIDA E-053-2016-1-GB-16 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders GB EP 17711971.6 Issued
NIDA E-053-2016-1-EP-03 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP National Stage 17711971.6 Issued
NIDA E-053-2016-1-SE-28 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SE EP 17711971.6 Issued
NIDA E-053-2016-1-RO-26 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders RO EP 17711971.6 Issued
NIDA E-053-2016-1-ES-13 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders ES EP 17711971.6 Issued
NIDA E-053-2016-1-SI-29 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SI EP 17711971.6 Issued
NIDA E-053-2016-1-SK-30 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders SK EP 17711971.6 Issued
NIDA E-053-2016-1-RS-27 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders RS EP 17711971.6 Issued
NIDA E-053-2016-1-PT-25 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PT EP 17711971.6 Issued
NIDA E-053-2016-1-NO-23 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders NO EP 17711971.6 Issued
NIDA E-053-2016-1-PL-24 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PL EP 17711971.6 Issued
NIDA E-053-2016-1-DK-12 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders DK EP 17711971.6 Issued
NIDA E-053-2016-1-CZ-10 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders CZ EP 17711971.6 Issued
NIDA E-053-2016-1-HR-18 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders HR EP 17711971.6 Issued
NIDA E-053-2016-1-NL-22 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders NL EP 17711971.6 Issued
NIDA E-053-2016-1-IE-20 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders IE EP 17711971.6 Issued
NIDA E-053-2016-1-IT-21 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders IT EP 17711971.6 Issued
NIDA E-053-2016-1-HU-19 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders HU EP 17711971.6 Issued
NIDA E-053-2016-1-GR-17 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders GR EP 17711971.6 Issued
NIAID E-118-2016-0-BR-04 Live Attenuated Zika Virus Vaccine BR National Stage 1120180683426 Abandoned
NCI E-016-2019-0-US-01 Methods Of Decreasing Influenza-induced Lethality Using Gastrin Releasing Peptide (GRP) Or Gastrin Releasing Peptide Receptor (GRPR) Antagonists US 62/729,662 Abandoned
NIDA E-053-2016-2-US-01 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF US 62/729,709 Abandoned
NIAID E-118-2016-0-US-14 LIVE ATTENUATED ZIKA VIRUS VACCINE US National Stage 16/083,652 Abandoned
NIAID E-102-2016-0-US-04 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE US National Stage 16/083,359 10808011 Issued PDF
NCI E-230-2020-0-US-01 Recurrence Gene Signature Across Multiple Cancer Types US 62/728,339 Abandoned
NIAID E-150-2022-0-US-01 COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING FILARIAL DISEASE US 62/728,312 Abandoned
NHLBI E-222-2022-6-US-01 Catheters and Manipulators with Articulable Ends US 62/728,413 Expired
NIDCD E-043-2016-0-US-07 MICRORNAS AND METHODS OF THEIR USE US National Stage 16/082,852 11655469 Issued PDF
NCI E-257-2009-1-US-24 Use Of IL-15 To Increase Thymic Output US DIV 16/123,431 1104-10-08 Issued PDF
NHGRI E-149-2017-0-PCT-02 BIOMARKERS OF ORGANIC ACIDEMIAS PCT PCT PCT/US2018/049757 Expired
NHGRI E-149-2017-0-EP-03 BIOMARKERS OF ORGANIC ACIDEMIAS EP National Stage 18788915.9 Abandoned
NIAID E-106-2016-0-EP-03 PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE EP National Stage 17712275.1 Abandoned
NCI E-241-2016-0-CA-04 Micro-Dose Calibrator CA National Stage 3073559 Issued
NCI E-241-2016-0-AU-03 Micro-Dose Calibrator AU National Stage 2018329661 Issued